Clinical trial
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
NCT02484443
Study timeline
Study start (actual)2016-02-04Date precision: day
Registry last updated2023-10-26
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Metastatic Osteosarcomaunresolved
Recurrent Osteosarcomaunresolved
Interventions
DinutuximabBIOLOGICAL
SargramostimBIOLOGICAL
Sponsors & collaborators
National Cancer Institute (NCI)lead sponsor
Mapped research locations
Las VegasNevada, United States4ChicagoIllinois, United States3St LouisMissouri, United States3New YorkNew York, United States2BostonMassachusetts, United States2DallasTexas, United States2BaltimoreMaryland, United States2San AntonioTexas, United States2MontrealQuebec, Canada2IndianapolisIndiana, United States2MinneapolisMinnesota, United States2OrlandoFlorida, United States2
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02484443 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.